InnoCan Pharma (TSE:INNO) has released an update.
InnoCan Pharma has reported a substantial increase in their first quarter 2024 revenues, reaching $6.8 million, which signifies a growth of over 334% from the previous year, largely due to their subsidiary BI Sky Global Ltd. Gross profit also rose significantly by 338% to $6 million. The company is anticipating a pivotal FDA meeting in July to discuss the market introduction of their LPT-CBD technology for chronic pain management.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
